The primary objective of this study is to compare the total costs to sites and payers of administering IV iron over the 30-day observation period for subjects with IDA who receive Ferric Carboxymaltose (FCM) relative to those who receive iron sucrose, iron dextran, and ferumoxytol.

The primary objective of this study is to compare the total costs to sites and payers of administering IV iron over the 30-day observation period for subjects with IDA who receive Ferric Carboxymaltose (FCM) relative to those who receive iron sucrose, iron dextran, and ferumoxytol.

Inclusion Criteria:

• Must present for the first dose of a current cycle of IV treatment for IDA
• Must be over 18 years of age
• Must be willing and able to provide informed consent, including permission to obtain information from their medical records.
• Must be able to read and understand English.

Exclusion Criteria:

• Subjects not diagnosed with IDA.
• Subjects requiring more than one treatment cycle within 30 days.
• Subjects receiving maintenance IV iron therapy.
• Subjects treated with IV iron within the 30-day period prior to study enrollment.
• Subjects who received investigational medication in the six months prior to the study.

Subjects presenting for IDA treatment